您在這裡

首頁 » Tokyo » Pharmaceuticals

Asahi Kasei Pharma Corp.

Asahi Kasei Pharma Corp.是一家日本的公司，位于Tokyo。 更詳細如下。

公司信息

  • 公司名稱: Asahi Kasei Pharma Corp.
  • 國家: Japan
  • 地址: Tokyo
  • 國際區號: 81
  • 電話: 03-3296-3600 (+81-03-3296-3600)
  • 傳真: 03-3296-3680 (+81-03-3296-3680)
  • 聯絡: Shiro Hiruta
  • 網站:
  • 產品列表: Pharmaceuticals
  • 分類活動: Pharmaceuticals
  • 類型: Manufacturers
  • 個人資訊: Our Transformation To A Holding Company/constituent Corporations Configuration Brings Independent, Autonomous Management To Each Operation, For Global Development Of Operations Informed By A Clear Perception Of The Market In Each Field. I Am Confident That This Is The Optimal Configuration For The Asahi Kasei Group, Given Our Diversity Of Strengths In A Wide Range Of Operations. Management Of The Constituent Corporations – Asahi Kasei Fibers, Asahi Kasei Chemicals, Asahi Kasei Construction Materials, Asahi Kasei Homes, Asahi Kasei Emd, And Asahi Kasei Pharma – Will Be Marked By Speed, Independence, And Autonomy. Asahi Kasei Corporation, As The Holding Company, Is Focused On Formulation Of Group Strategy, Monitoring The Conduct Of Group Operations, Optimal Allocation Of Group Resources, And Group-level Corporate Research And Development. The Seven Constituent Corporations Bear Financial Responsibility, And Strive To Heighten Assets Efficiency And Productivity. They Hold Decision-making Authority For Their Own Operations And Their Own Cash Flow Based On Midrange Business Plans And Annual Budgets As Approved By The Holding Company. The Constituent Corporations Perform R&d For And Related To Their Operations, While The Holding Company Focuses On R&d Projects Which Will Advance The Transformation To A High-growth, High-earnings Group. Special Emphasis Is Placed On R&d In The Fields Of Electronics, Health Care, Environmental Preservation, And Energy Conservation. Corporate Governance In Preparation For The Transformation To A Holding Company/constituent Corporations Configuration, An Executive Officer System Was Adopted In June 2003 To Effect Clear Separation Of Management And Oversight Functions. Clarification Of Management Responsibility Will Also Serve To Heighten Speed And Transparency, For Expanded Earnings And Greater Corporate Value. The Executive Officer System Is Implemented In Each Constituent Corporation As Well As In The Holding Company, With Authority And Responsibility For Management Held By The President And Executive Officers Of Each Corporation. The President Of The Holding Company Oversees The Executive Management And Performance Of The Constituent Corporations, While The Holding Company Board Of Directors Oversees The Executive Management And Performance Of The Holding Company And The Group. For Both The Holding Company And The Constituent Corporations, The Term Of Office Of Directors And Executive Officers Is One Year, With Management Results And Performance Reviewed Each Fiscal Year To Ensure Heightened Speed. A Group Advisory Committee Will Be Established; It Will Include Outside Advisors And Reflect Their Advice In Its Basic Pursuit Of Enhancing And Enriching Corporate Governance. Beginning With Fiscal 2003, We Are Closing Accounts On A Quarterly Basis As Part Of A Proactive Effort To Enrich Disclosure To Our Stakeholders.
  • 地區: Tokyo
  • 行業: Pharmaceuticals
更多鏈接

  • Deetex Shokai K.k.
  • Shiga Co. Ltd.
  • Asahi Kasei Pharma Corp.
  • Nissan Chemical Ind. Ltd.
  • R & C Tours Co. Ltd.

    •         ‹ 上一頁 | 下一頁 ›
    • 發表回應前，請先登入